Decinova Therapeutics
A differentiated stromal-cell platform. Built through translational development.
Decinova is advancing its proprietary Decidua stromal-cell platform for therapeutic development and strategic partnering.
Historical platform evidence and development experience. See the DSC Platform and Publications pages for context.
DSC Flagship Section
From Decidual Biology to a Clinical-Stage Development Platform
DSC originated from research into the unique immunological environment of the human decidua — a tissue naturally adapted to regulate complex immune interactions at the maternal–fetal interface.
That biology led to the development of a distinct stromal-cell platform with potent immunomodulatory properties and characteristics that differentiate DSC from conventional stromal-cell sources.
Decinova’s priority development and partnering focus is steroid-refractory acute graft-versus-host disease (SR-aGVHD) — a severe, potentially life-threatening complication of allogeneic stem-cell transplantation.
Over more than 15 years, the platform has accumulated experience across:
- Cell biology and mechanism
- Process development and manufacturing
- Cryopreservation and product handling
- Preclinical and toxicology development
- Clinical administration
- Regulatory development
- Published clinical research
This translational history now provides the foundation for the next stage of DSC development.
Published Clinical Evidence in Severe Acute GVHD
Acute graft-versus-host disease remains a major cause of morbidity and mortality following allogeneic hematopoietic stem-cell transplantation. Patients who fail corticosteroid treatment represent a particularly difficult population with substantial unmet medical need.
DSC has generated published clinical experience in severe acute GVHD and provides the foundation for continued clinical development of the platform.
Decinova’s objective is to advance the program through its next clinical-development stage and establish the evidence required for broader regulatory and commercial development.
Published long-term follow-up in 21 patients treated with DSCs for severe acute GVHD
Source: Sadeghi et al., PMID: 31173898. Presented as published clinical follow-up data, not as definitive evidence of efficacy.
Partnering
Selected Partner Capabilities
Alongside the DSC platform, Decinova supports selected partner programs through scientific judgment, translational-development perspective, planning and technology-transfer strategy.
Scientific and Translational Program Assessment
Evaluating the scientific rationale and translational maturity of a partner’s cell-therapy program.
Development Strategy and Roadmap Support
Planning perspective on the path from research platform to therapeutic product.
Technology-Transfer Strategy
Strategy for transferring cell-technology know-how into a partner’s own development or manufacturing setting.
Explore a strategic partnership with Decinova.
We’re open to conversations across a specific set of routes:
- DSC licensing or co-development
- Strategic investment
- Selected translational-development or technology-transfer discussions